Filing identity and reporting period
Important discrepancy: The supplied filing is Rexahn Pharmaceuticals, Inc.’s unaudited Form 10-Q for the quarter ended September 30, 2014, not an Opus Genetics, Inc. filing. The summary below describes Rexahn’s filing and should not be attributed to Opus Genetics.
Business context
Rexahn was a clinical-stage biopharmaceutical company developing cancer treatments. It reported no product revenue and said it expected to incur losses through 2014 and beyond. Its pipeline included one Phase II candidate, two Phase I candidates, and preclinical programs.
Financial performance and liquidity
| Metric | Three months ended September 30, 2014 | Nine months ended September 30, 2014 | Comparable 2013 period |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Operating expenses | $3.14 million | $9.42 million | $1.82 million and $5.65 million |
| Net loss | $1.91 million | $16.31 million | $2.14 million and $6.78 million |
| Net loss per share | $0.01 | $0.09 | $0.02 and $0.06 |
For the nine months, research and development expense rose 112% to $4.80 million, primarily reflecting advancement of drug candidates; general and administrative expense rose 44% to $4.33 million. The nine-month loss included a $6.79 million noncash unrealized loss on warrant liabilities. In the third quarter, warrant revaluation instead produced a $1.20 million gain. With no revenue, a revenue-based margin is not meaningful.
Operating cash use was $8.13 million for the nine months, versus $5.74 million in 2013. Financing provided $24.84 million, including net proceeds of $18.63 million from a January offering and $5.95 million from warrant exercises. Investing used $20.43 million, principally to purchase marketable securities. At September 30, cash and cash equivalents were $14.97 million and marketable securities were $20.61 million; combined, these totaled $35.59 million. Current assets were $36.34 million, current liabilities $7.86 million, and total liabilities $7.86 million, including $5.38 million of warrant liabilities. The filing reports no conventional borrowings.
Changes, outlook, and risks
- Compared with 2013, nine-month net loss increased substantially, mainly due to the warrant fair-value loss and higher operating expenses. Third-quarter net loss was lower year over year, partly because warrant remeasurement shifted from a loss to a gain.
- Management said available cash, cash equivalents, and marketable securities should fund current activities for at least 24 months. It also stated that additional capital would be needed to continue drug development and might not be available on acceptable terms; without it, research programs could be reduced.
- Archexin entered a Phase IIa trial in metastatic renal cell carcinoma; management expected to complete the initial safety component in early 2015. RX-3117 and Supinoxin were in Phase I dose-escalation studies; expected enrollment or trial completion dates were in early 2015. These are forward-looking expectations, not assured outcomes.
- Key risks include clinical-trial delays or failure, regulatory uncertainty, early-stage development, dependence on external research organizations, financing needs, and the ability to secure collaborators and protect intellectual property. Management said clinical-program completion costs and timing could not be reliably estimated.
- Research and development vendor agreements had an estimated total contract value of about $30 million, of which about $22.72 million had been paid since inception; the agreements were terminable with notice. No disclosed KRICT or university-license development milestones had occurred by quarter-end.
- Warrant liabilities are Level 3 fair-value estimates sensitive to assumptions, including the estimated probability of a fundamental transaction. Available-for-sale securities had $42,041 of unrealized losses, which the company considered temporary.
Most important facts to verify
- Confirm the intended issuer: the provided document identifies Rexahn Pharmaceuticals, Inc., not Opus Genetics, Inc.
- Review the cash runway against actual operating cash use, planned trial spending, and the assumptions behind management’s 24-month estimate.
- Check subsequent clinical-trial progress and whether the stated 2015 timelines were achieved.
- Assess potential dilution and warrant exposure, including the warrant liability’s valuation assumptions and remaining warrants.
- Review the full filing and later disclosures for financing, contingencies, and changes to development plans.